宫颈癌是女性最常见的妇科恶性肿瘤之一，以顺铂为基础的同步放化疗能明显提高中晚期患者的生存率，但是还有相当数量的病例在治疗后出现局部复发和远处转移。肿瘤内在的放化疗敏感性也是宫颈癌治疗成败的关键因素。申请人前期研究发现miR-492在宫颈癌治疗抗拒组患者中较治疗敏感组患者显著低表达，但具体机制尚不清楚。围绕这一研究结果,本项目将阐明miR-492影响宫颈癌细胞放化疗敏感性的分子机制，确定miR-492增敏的下游效应基因及其所受的上游调控作用；并在动物水平进一步确证miR-492的增敏作用。通过文献阅读、microRNA靶基因预测网站搜寻以及前期预实验的结果，我们初步锁定p53/miR-492/EGFR调控网络为本课题主要研究内容，为miR-492最终成为预测宫颈癌放化疗敏感性标志物提供坚实的理论依据。

Cervical cancer is a leading cause of cancer death in women worldwide. Platinum based concomitant chemoradiotherapy significantly improved the survival rate of patients with advanced cervical cancer. However, clinical outcomes vary significantly and are difficult to predict. Tumor intrinsic chemoradiotherapy sensitivity is one of the crucial reasons for concomitant chemoradiotherapy failure in cervical cancer. In our previous study, we found miR-492 was significantly down-regulated in resistant group compared with sensitive group (P<0.05). But the underlying mechanism is unclear. The aim of this study is to elucidate the role of miR-492 in regulating chemoradiotherapy sensitivity of cervical cancer cells. We propose to identify its downstream effecor genes and upstream regulatory mechanism. And we will also validate the chemoradiosensitizing effect of miR-492 on cervical cancer cells in vivo. Combined with bioinformatics analysis,we prefer p53/miR-492/EGFR regulatory network as the main content of this study. Our study will provide support for the use of miR-492 as a biomarker to predict chemoradiotherapy sensitivity in cervical cancer.